Nautilus Biotechnology, Inc. (NAUT) — Analyst outlook / Analyst consensus target is. Based on 5 analyst ratings, the consensus is bullish — 3 Buy, 1 Hold, 1 Sell.
The consensus price target is $2.50, representing a downside of 18.3% from the current price $3.06.
Analysts estimate Earnings Per Share (EPS) of $-0.45 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.56 vs est $-0.45 (missed -23.8%). 2025: actual $-0.47 vs est $-0.53 (beat +10.5%). Analyst accuracy: 85%.
NAUT Stock — 12-Month Price Forecast
$2.50
▼ -18.30% Downside
Average Price Target
Based on 5 Wall Street analysts offering 12-month price targets for Nautilus Biotechnology, Inc., the price target is $2.50.
The average price target represents a -18.30% change from the last price of $3.06.
NAUT Analyst Ratings
Buy
Based on 5 analysts giving stock ratings to Nautilus Biotechnology, Inc. in the past 3 months
EPS Estimates — NAUT
85%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$0.56
vs Est –$0.45
▼ 19.2% off
2025
Actual –$0.47
vs Est –$0.53
▲ 11.7% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — NAUT
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
